Study Title	Anticoagulation for Stroke and Dementia Prevention in Atrial Myopathy
Funding I/C	NHLBI
Study Description	Atrial myopathy (characterized by abnormalities in left atrial function and size) is independently associated with higher risk of ischemic stroke and dementia. We hypothesize that a direct oral anticoagulant can significantly reduce the risk of a composite of ischemic stroke, mild cognitive impairment, dementia, and all-cause death in older adults with atrial myopathy and without prior ischemic stroke, mild cognitive impairment or dementia, or atrial fibrillation.
Study Design	CREATIVITY is a Phase 3 multicenter double blind randomized controlled trial. The aim of CREATIVITY is to determine whether a direct oral anticoagulant can significantly reduce the risk of a composite of ischemic stroke, mild cognitive impairment, dementia, and all-cause death in older adults with atrial myopathy and without prior ischemic stroke, mild cognitive impairment or dementia, or atrial fibrillation. There will be 2 arms: one arm receiving a direct oral anticoagulant and the other arm receiving a placebo. Participants will be randomly assigned to the 2 arms.
IRB	Vanderbilt University Medical Center sIRB
Coordinating Center	Vanderbilt Clinical Coordinating Center
Study Length	Plan to submit a UG3/UH3 grant proposal to the NHLBI. The UG3 phase is 1 year and the UH3 phase is 6 years for a total duration of 7 years or 84 months. 2-year recruitment period; participants followed minimum 36 months and maximum 60 months.
Study Enrollment #	1000
Eligibility Criteria	**Inclusion Criteria** -Older adults aged ≥65 years with LA reservoir strain <27% and CHA_2DS_2-VASc ≥3 **Exclusion Criteria** -Prior ischemic stroke, mild cognitive impairment or dementia, or atrial fibrillation
Total # of Sites	20
Site Requirements	Study sites will need to have the following at their site to be considered: • Clinical 2-D ECHOS • Tech available for training and measuring LA reservoir strain • Research coordinator familiar with cardiac clinical trials
Site Investigator Qualifications	Site Investigators should have the following: • Practicing ABIM board-certified cardiologist • Prior cardiac clinical trial experience as Co-I or PI
Key Timeline Dates:	The following dates are projections and subject to change: **Site Selection Decisions**: June 2026 **Site Selection Notifications:** July 2026 **Enrollment begins:** January 2027 **Last Patient/Last Visit:** January 2032 **Study Closure:** July 2032